Market Brief

The articles are produced in Chinese only.


李樂雯女士 (Phoenix Li)

現任職輝立分行經理,對股票、期貨投資經驗豐富。 樂意為客戶提供投資分析及買賣策略。 歡迎各位來電交流心得。

國藥控股 (1099.HK)

Tuesday, May 14, 2019 Views3650

1099 國藥控股


Business Summary

Sinopharm Group Company Limited is principally engaged in the distribution of pharmaceutical products and medical equipment. The Company operates through three business segments.

The Pharmaceutical Distribution segment is engaged in the distribution of medicines, medicine devices and pharmaceutical products to hospitals, other distributors, retail drug stores and clinics.

The Retail Pharmacy segment is engaged in the operation of medicine chain stores. The Other Business segment is engaged in the distribution of laboratory supplies, the manufacture and distribution of chemical reagents, as well as the production and sales of pharmaceutical products.

The Company is also engaged in the provision of pharmaceutical logistics services and property rental business in China through its subsidiaries.


Investment Theme


First quarter net profit of 1.145 billion yuan rose 28%.

The number of patients has grown strongly. It is expected that the Group's profit growth will be stable in the first half of this year, and the national drug centralized purchasing policy will have limited impact on its revenue growth this year and next.

It is believed that Sinopharm's acquisition of Chinese scientific equipment to enter the fast-growing equipment distribution market is believed to help promote the Group's future growth.

By the end of 2018, the pharmaceutical retail business had covered 229 cities in 30 provinces across the country, with a total of 5,183 pharmacies, an increase of 740 over the same period last year.

Sinopharm has fallen to the lower limit of 30 yuan in the past three years. Considering the impact of digesting the two-vote system and increasing market share, the price-earnings ratio is only 11 times the lowest in 3 years, even if there is uncertainty in the purchase of 7+4, downward The risk of a breakthrough is not great.



Buy Price: 30.4 Target Price: 36 Cut Loss: 28.5




This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email :

Enquiry & Support
The Complaint Procedures
Louis Talk
Investor Notes
Free Subscribe
Contact Us